Health-related quality of life in patients with HR+/HER2- early breast cancer treated with ribociclib plus a nonsteroidal aromatase inhibitor: results from the NATALEE trial

By sjmartinez • March 1, 2025

Fasching PA, Slamon D, Nowecki Z, Kukielka-Budny B, Stroyakovskiy D, Yardley DA, Huang CS, Chan A, Chia S, Martín M, Rugo HS, Loi S, Hurvitz S, Untch M, Afenjar K, Fresco R, Danyliv A, Ferrusi I, Li Z, Hortobagyi G. Health-related quality of life in patients with HR+/HER2- early breast cancer treated with ribociclib plus a nonsteroidal aromatase inhibitor: results from the NATALEE trial. Clin Cancer Res. 2025 Feb 28. doi: 10.1158/1078-0432.CCR-24-1724. Epub ahead of print. PMID: 40019493.

Tags: Hematology/Oncology, Publications

Phase 2 Trial of 89Zr-Deferoxamine-Daratumumab for CD38-targeted Immuno-PET/CT Detection of Multiple Myeloma

Ulaner GA, Kuker RA, Diamond B, Hoffman J, Motwani P, Goldenson B, Homsi Y, Schiller G, Thomsen B, Vossen A, Kazandjian D, Landgren CO. Phase[...]

A CCL21 gene-modified dendritic cell vaccine combined with pembrolizumab in advanced non-small cell lung cancer: a phase I trial

Oh MS, Lisberg AE, Dumitras C, Tran LM, Salehi-Rad R, Krysan K, Lim RJ, Shabihkhani M, Romero T, Li S, Zeng W, Jing Z, Li[...]

Correction to: Utilizing natural language processing (NLP) to identify breast cancer-associated lung metastases from pathology reports to delineate characteristics of this site of recurrence

Valentín López JC, Ho A, Hughes KS, Bardia A, Vidula N. Correction to: Utilizing natural language processing (NLP) to identify breast cancer-associated lung metastases from[...]